Valeant Analysts Aren't Alone in Thinking `Sell' Is a Dirty Word
- Analysts stick with falling stocks even after investors bail
- 95 percent of all stock-pickers have `buy' or `hold' rating
Valeant Analyst: More Bad News to Come
This article is for subscribers only.
It’s easy to pick on the Wall Street analysts who cover Valeant Pharmaceuticals International Inc. Many loved the stock on the way up -- and kept right on loving it on the way down.
But the fact is, analysts in every industry rarely say “sell.” Only about 5 percent of the ratings on 1,778 U.S. companies worth at least $1 billion are “sells” or the equivalent, according to data compiled by Bloomberg. For drug stocks like Valeant, that figure is even lower: 2.5 percent.